A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

March 31, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions

Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

GB1211

GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.

DRUG

Placebo

Placebo is administered as inhalation once a day